Dr. Uribe is Chief of the Division of Spinal Disorders, Volker K. H. Sonntag Chair of Spine Research, and Vice Chairman of Neurosurgery at Barrow Neurological Institute
Dr. Uribe Becomes Aclarion's 3rd KOL With Access to a Diagnostic Center Authorized to Perform Nociscans
BROOMFIELD, CO, Jan. 22, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – Aclarion, Inc. ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a healthcare technology company that is leveraging biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain, announced today that Nociscan is now available in the greater Phoenix, AZ market at the Barrow Neurological Institute with Dr. Juan Uribe and other area physicians treating chronic low back pain.
Dr. Uribe's practice emphasizes a comprehensive approach to treating the spine and applying minimally invasive spine surgery to complex degenerative disease. "I have dedicated my life to alleviating the pain and suffering associated with spinal disorders. Low back pain is an extremely debilitating condition that lacks a noninvasive tool helping me identify the location of a patient's pain. I am pleased Nociscan is now available in the greater Phoenix market, which will help us continue to advance more accurate diagnosis and treatments for low back pain," said Dr. Uribe.
Chronic low back pain (cLBP) is a leading cause of opioid addiction in the U.S. and the single most expensive diagnosis in the United States. Aclarion's Nociscan solution is the first evidence-supported SaaS platform to noninvasively help physicians distinguish between painful and nonpainful discs in the lumbar spine. Nociscan objectively quantifies chemical biomarkers demonstrated to be associated with disc pain. Biomarker data is entered into proprietary algorithms to highlight if a disc may be a source of pain. When used with other diagnostic tools, Nociscan provides critical insights into the location of a patient's low back pain, giving physicians clarity to optimize treatment strategies.
"Dr. Uribe is a renowned neurosurgeon at one of the world's leading neurological institutes, Barrow," said Ryan Bond, Chief Strategy Officer of Aclarion. "Throughout Dr. Uribe's career he has rejected norms and advanced the treatment of chronic low back pain through research, education and adopting innovation. We are pleased that he and the medical community in Phoenix will now have access to Nociscan."
Aclarion recently announced the completion of the 1,000th commercial Nociscan exam and pointed to additional KOLs gaining access to MRIs as a key catalyst for supporting scan volume growth in 2024. Activation of the Phoenix market represents the first such key catalyst of 2024.
Uribe博士是巴羅神經學研究所脊柱疾病部主任、Volker K.H. Sonntag脊柱研究主席和神經外科副主任
Uribe 博士成爲 Aclarion 的第三位關鍵人物，可進入授權進行諾西斯掃描的診斷中心
科羅拉多州布魯姆菲爾德，2024 年 1 月 22 日（GLOBE NEWSWIRE）— 通過 NewMediaWire — Aclarion, Inc.（“Aclarion” 或 “公司”）（納斯達克股票代碼：ACON，ACONW）是一家利用生物標誌物和專有的增強智能算法幫助醫生識別慢性腰痛位置的醫療技術公司。該公司今天宣佈，Nociscan現已在亞利桑那州大菲尼克斯市場的巴羅神經學研究所上市，胡安·烏里韋博士和其他地區醫生治療慢性腰痛。
烏里韋博士的執業重點是採用綜合方法治療脊柱，並將微創脊柱手術應用於複雜的退行性疾病。“我畢生致力於減輕與脊柱疾病相關的疼痛和痛苦。腰痛是一種極其虛弱的疾病，缺乏一種非侵入性工具來幫助我識別患者疼痛的位置。我很高興Nociscan現在可以在大菲尼克斯市場上市，這將幫助我們繼續推進更準確的腰痛診斷和治療，” 烏里韋博士說。
慢性下背痛（clBP）是美國阿片類藥物成癮的主要原因，也是美國最昂貴的診斷。Aclarion的Nociscan解決方案是第一個以無創方式幫助醫生區分腰椎間盤疼痛和非疼痛的SaaS平台。Nociscan 客觀地量化了已證明與椎間盤疼痛相關的化學生物標誌物。生物標誌物數據被輸入到專有算法中，以突出椎間盤是否可能是疼痛的來源。與其他診斷工具一起使用時，Nociscan可以提供有關患者下背部疼痛位置的關鍵見解，從而使醫生能夠清晰地優化治療策略。
Aclarion首席戰略官瑞安·邦德說：“烏里韋博士是世界領先神經學研究所之一巴羅的著名神經外科醫生。”“在烏里韋博士的整個職業生涯中，他拒絕了規範，通過研究、教育和創新推動了慢性下背痛的治療。我們很高興他和菲尼克斯的醫學界現在可以使用Nociscan。”
Aclarion最近宣佈完成第1000次商業Nociscan考試，並指出獲得核磁共振成像的更多KOL是支持2024年掃描量增長的關鍵催化劑。菲尼克斯市場的激活是2024年的第一個此類關鍵催化劑。
